To examine the influence of perioperative thiazolidinedione (TZD) on cancer-specific outcomes in patients with diabetes mellitus (DM) undergoing radical cystectomy (RC) for urothelial carcinoma (UC).
Patients and Methods
A retrospective cohort of 173 patients with DM undergoing RC from 2005 to 2010 was identified. Of those, 53 were on TZD treatment at the time of RC, with 33 patients taking pioglitazone. Baseline clinicopathological characteristics, as well as cancer-specific survival (CSS), recurrence-free survival (RFS), and overall survival (OS) were compared between the patients on and off TZD therapy at the time of RC. In subgroup analysis, outcomes in patients specifically taking pioglitazone at the time of RC were compared to those not on a TZD.
Results
Baseline clinicopathological characteristics were similar between patients on and off TZD therapy at the time of RC. Overall, the median CSS rate was not reached in either group (P = 0.7). The estimated 5-year CSS was 67.8% in the non-TZD group and 66.3% in the TZD group. On multivariate analysis incorporating patient age, pathological T-staging, and adjuvant chemotherapy, TZD use was found not to be a significant predictor for CSS (hazard ratio 1.20, 95% confidence interval 0.66-2.17; P = 0.5). Additionally, RFS (P = 0.3) and OS (P = 0.2) were also similar between the two groups without adjusting for other variables. Comparison between patients taking pioglitazone vs patients not taking TZD yielded similar CSS (P = 0.2), RFS (P = 0.5), and OS (P = 0.2).
Introduction
Much debate has surrounded the link between thiazolidinedione (TZD) use and urothelial cancer (UC) of the bladder. First demonstrated in animal studies, urothelial carcinogenesis observed after TZD treatment was attributed to crystallisation of calcium-and magnesium-containing uroliths and the associated alterations in urine composition [1] . Consistent with these findings, rosiglitazone was also described to enhance hydroxybutyl(butyl)nitrosamine-induced urothelial carcinogenesis [2] . Subsequent data from the PROspective pioglitAzone Clinical Trial in macrovascular Events (PROactive), as well as the interim analysis of an observational cohort study conducted in the Kaiser Permanente of Northern California (KPNC) database, seemed to implicate a similar association between the incidence of UC with prolonged pioglitazone intake in humans [3, 4] .
As a result, the USA Food and Drug Administration (FDA) issued a public safety announcement in 2011 regarding the increased risk of UC after >1 year of treatment with pioglitazone. Conjointly, recommendations were made against the use of pioglitazone in patients with active UC. Soon after, the European Medicines Agency (EMA) followed suit, also issuing warnings about a slightly increased risk of UC with pioglitazone and prohibiting its use in patients with history of bladder cancer or uninvestigated haematuria.
Since then, emerging evidence from the long-term observational data of the PROactive clinical trial, as well as the final report of the KPNC cohort study, suggested that the increased risk of UC with pioglitazone use observed early on had resolved with long-term follow-up [5, 6] . Moreover, no data about the clinical effects of TZD in patients with active UC exists in the current literature. To this end, we aimed to examine the role of TZD at the time of radical cystectomy (RC) in patients with diabetes mellitus (DM) diagnosed with UC. On the basis of the limited specificity of TZD-associated tumorigenesis in rats, we hypothesised that perioperative TZD use does not affect cancer-specific outcomes. [7] , receipt of intravesical immunotherapy with BCG, and neoadjuvant and adjuvant systemic chemotherapy. All histological specimens were reviewed at the M.D. Anderson Cancer Center by subspecialty genitourinary pathologists. Recurrent cancers after RC were detected on imaging with or without histological evidence, and were correlated with the clinical course after RC. Deaths were designated as cancer-specific when patients succumbed to disease within 12 months of metastasis or due to perioperative complications within 90 days of RC. Survival was calculated from the date of RC.
Patients and Methods

After
The primary comparison was between the cancer-specific survival (CSS) in patients on and off TZD therapy at the time of RC. A multivariate Cox proportional hazards model was used to evaluate whether perioperative TZD intake independently predicted for CSS. In addition, the recurrencefree survival (RFS) and overall survival (OS) of the two groups were analysed. As the FDA warning was limited to pioglitazone, subgroup analysis was performed comparing the RFS, CSS, and OS of patients specifically taking pioglitazone vs those not on TZD at the time of RC.
Statistical analysis was performed using STATA/SE version 14.1 statistical software (Stata Corp. LP, College Station, TX, USA). Continuous variables were summarised using the mean and standard deviation (SD), and categorical variables using frequency count and percentage. Two-sample Wilcoxon ranksum test and Pearson's chi-squared tests were used for comparison of continuous and categorical variables, respectively. CSS, RFS and OS were estimated using the Kaplan-Meier method and compared using the log-rank test. Multivariate analysis was performed using a Cox regression model. All tests were two-sided with a P < 0.05 considered statistically significant.
Results
Of the 173 patients with DM undergoing RC, 53 were on TZD treatment at the time of RC. Baseline demographics are shown in Table 1 [7, 8] . Notably, BMI in the TZD group was higher (33.2 vs 30.3 kg/m 2 , P = 0.006), possibly reflective of their higher severity of metabolic syndrome. In addition, slightly more patients in the non-TZD group had a smoking history (95.8% vs 86.8%, P = 0.031). Clinical staging was similar between the two groups. In the non-TZD group, 45.8%, 41.7% and 12.5% were staged <cT2, cT2 and >cT2, respectively. The corresponding percentages in the TZD group were 47.2%, 41.5% and 11.3% (P = 0.9). The proportions within each group having undergone intravesical BCG and neoadjuvant chemotherapy were similar (Table 1 ).
In the non-TZD group, 51.6%, 17.5% and 30.8% had pathological staging <pT2, pT2 and >pT2, respectively. The corresponding percentages in the TZD group were 54.7%, 7.5%, and 37.7% (P = 0.5). In addition, similar proportions of patients had pathologically node-positive (non-TZD 18.4% vs TZD 22.6%, P = 0.3) and metastatic disease (non-TZD 5% vs TZD 0%, P = 0.2). Similar rates of patients received adjuvant chemotherapy in each group.
The mean (range) follow-up after RC was 49.3 (0.5-115) months for the non-TZD group and 48.1 (0.4-130.7) months for the TZD group (P = 0.7). Overall, 35 (29.2%) and 17 (32%) deaths due to UC occurred during the follow-up period in the non-TZD and TZD groups, respectively. For both the non-TZD and TZD groups, median CSS was not reached (P = 0.7; Fig. 1a) . The estimated 5-year CSS was 67.8% (95% CI: 57.9-75.9%) in the non-TZD group vs 66.3% (50.7-78.0%) in the TZD group. On multivariate analysis incorporating age, pT staging, and adjuvant chemotherapy, TZD use was found not to be a significant predictor for CSS [hazard ratio (HR) 1.20, 95% CI: 0.66-2.17; P = 0.5] (Table 2 [7] ). Furthermore, no difference was found in the RFS (median RFS non-TZD 31 months, 95% CI 16-57 months vs TZD 45 months, 95% CI: 24-72 months, P = 0.3) and OS (median OS non-TZD 73 months 95% CI: 42-99 months vs TZD 49 months, 95% CI: 26-70, P = 0.2) in the two groups (Fig. 1 ).
In all, 33 patients were specifically on pioglitazone treatment at the time of RC. Similar to the TZD group overall, patients taking pioglitazone at the time of RC had higher BMIs and a lower incidence of smoking history than the non-TZD group (Table 1) . The median (95% CI) RFS, CSS and OS for the patients taking pioglitazone was 37 (14-88) months, 71 (24-not reached) months, and 46 (23-90) months, respectively ASA, American Society of Anesthesiologists classification; CIS, carcinoma in situ. *BCG unresponsiveness was defined as high-grade tumour recurrence within 6-9 months of the last exposure to BCG despite adequate BCG treatment (at least five of six induction instillations and two of three maintenance doses of BCG) [8] . † Clinical and pathological tumour staging classified according to the seventh edition of the AJCC Staging Manual [7] . Statistically significant values denoted in bold. (Fig. 2) . There was no difference in RFS, CSS, or OS between patients on pioglitazone and no TZD at the time of RC.
Discussion
To our knowledge, the present study is the first to evaluate the clinical effects of oral TZD on patients with active UC. No detriment was seen in regards to the CSS, RFS, or OS in patients taking TZD at the time of RC. As the FDA and EMA have recently reiterated their warnings against the use of pioglitazone in patients with active UC [9] , no prospective study is possible to test the validity of the concern for cancer exacerbation. Barring future changes by these agencies, our present study serves as a unique comparison of the clinical outcomes of patients with UC with and without perioperative use of TZD.
Previously, one small study reported a similar pathological staging distribution between patients with DM undergoing RC with (nine patients) and without (24) pioglitazone treatment [10] . Similarly, no difference was seen between the TZD and non-TZD groups in the present study. However, our present cohort was composed of significantly higher proportion of patients with non-muscle-invasive bladder cancer (51.6% vs 24.1% in non-TZD patients and 54.7% vs 22.2% in TZD patients). This discrepancy could either be due to difference in practice patterns or a statistical artefact of the small sample size in the previous study.
The lack of difference in oncological outcomes due to TZD treatment corroborates with long term follow-up data from the PROactive trial and the KPNC longitudinal cohort study, showing no difference in the incidence of bladder cancer between TZD users and controls [5, 6] . It has been suggested that the resolution of the statistical difference on the longterm follow-up may be due to a time-dependent manner in which bladder cancer was induced by pioglitazone. However, this theory was disproven in a separate analysis of the KPNC study, in which similar results were found when patients were censored at 1 year after discontinuation of pioglitazone [6] . These results were corroborated by other prospective and retrospective studies in diverse populations [11, 12] . A systematic review of this topic reported discrepant results, with some studies finding no association, some a modest association, whilst others more pronounced associations [13] .
On the other hand, evidence for increased bladder carcinogenesis with TZD intake has been modest at best. The only study to date implicating TZD as a promoter of carcinogenesis in the setting of active UC was conducted in Fischer-344 female rats using the hydroxybutyl(butyl) nitrosamine-induced tumour model [2] . Rosiglitazone, even when administered relatively late in the carcinogenic process, led to decreased cancer latency and a large increase in cancer incidence. The tumorigenic effect was thought to be due to signalling via the peroxisome proliferator-activated receptor c (PPARc) pathway, a transcription factor involved in the regulation of glucose and lipid homeostasis, inflammation, proliferation, and differentiation [14] . The exact role of PPARc activation in carcinogenesis remains uncertain and seems disparate in different tumour types [14] . Germane to bladder cancer, PPARc is thought to be intimately involved in the regulation of vascular endothelial growth factor [7] . † Surgical downstaging was defined as the finding of nonmuscle-invasive disease (≤pT1) in the RC specimen in patients with muscle invasive disease (≥cT2) at transurethral resection of bladder tumour subsequent to neoadjuvant chemotherapy. Statistically significant values denoted in bold. (VEGF), leading to increased angiogenesis and tumour growth [15] . On the other hand, PPARc agonists have also been repeatedly shown to decrease UC viability [16] and to inhibit cellular proliferation [17] and tumour growth [18] . Regardless of its mechanism of action, the tumour enhancing ability of TZD has not been replicated in other animal studies or with data from human trials.
The evidence for the induction of UC by pioglitazone is equally dubious. Notwithstanding its statistical significance, the PROactive trial found an increase of only eight cases in a total of 2 605 patients on pioglitazone therapy, translating to a difference of 0.3% compared to the control group [3] . The KPNC data supporting enhanced tumorigenesis were equally suspect. The 5-year interim analysis revealed only a weak signal of increased UC incidence in prolonged pioglitazone users (odds ratio 1.4, 95% CI: 1.03-2.10) and no such increase in the overall cohort [4] . Despite the emerging favourable long-term evidence [5, 6] , the FDA recently chose to retain its warning that pioglitazone use is possibly associated with a higher risk of UC [9] .
The results from the present study lead to the provocative conjecture that notwithstanding its dubious link to the induction of UC, TZD can be safely used in the setting of active UC. However, this hypothesis needs further validation in larger muscle-invasive bladder cancer sample groups. As RC theoretically removes the greatest proportion of tumour burden, it is vital to also assess cancer-specific outcomes in patients on and off TZD therapy whilst undergoing other forms of bladder-sparing treatments, such as radical trimodality therapy, systemic chemotherapy, and immunotherapy. Furthermore, the outcomes in patients with non-muscle-invasive bladder cancer warrant detailed examination, specifically scrutinising TZDs' influence on outcomes after intravesical therapy, rates of recurrence, and progression to muscle-invasive bladder cancer. However, prospective studies to answer these questions are currently prohibited by the existing warnings from the FDA and EMA. Efforts are underway at our institution to retrospectively evaluate the effect of TZD in these populations.
The present study was not without limitations. Due to the retrospective nature of the review, the duration of TZD intake was not standardised before or after RC. As such, it is conceivable that patients may have discontinued therapy upon the FDA Drug Safety Communication issued in August 2011, leading to a dilution of the treatment effect over time.
To combat this problem, we restricted our retrospective query to the end of 2010 in attempt to limit the number of patients terminating TZD therapy shortly after RC. Furthermore, duration of TZD use before and after RC could not be universally obtained in the present retrospective cohort. Thus, time-dependent effects of TZD use on active UC may not have been evident in the present analysis. With the FDA/ EMA label warnings still in place, an effective prospective study in the clinical setting of active UC is impossible.
Conclusions
We present the first analysis of the clinical effects of oral TZD intake on patients with active UC undergoing RC. After RC, CSS, RFS, and OS were not compromised in patients on TZD treatment or specifically taking pioglitazone at the time of RC.
